Tenax announces USPTO grants notice of allowance for patent application

Tenax Therapeutics announced that the United States Patent and Trademark Office, USPTO, has allowed its patent application with claims covering the use of TNX-103, TNX-102, TNX-101, the active metabolites of levosimendan and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients and, titled: “LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION.” This new patent, once granted, will provide significant added IP protection through December 2040. The Notice of Allowance indicates that the USPTO plans to grant Tenax expanded IP rights to the use of oral, subcutaneous, and intravenous administration of levosimendan, as well as its active metabolites for the treatment of PH-HFpEF, at all therapeutic doses.